Nayzilam®
In the U.S., Nayzilam® (midazolam) is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 12 years of age and older.
Prescribing information USA
-
Nayzilam® Prescribing information USA
February-2021 | pdf file, 1422 kb
Related website
Nayzilam® product website (for US residents only)
www.nayzilam.com